Ropes & Gray advised Kailera Therapeutics, Inc. on the transaction. Kailera Therapeutics, Inc. (“Kailera”) announced raising $400 million in Series A financing. Kailera announced its launch...
Kailera Therapeutics’ $400 Million Series A Financing
Serán Bioscience’s $200 Million Growth Transaction
Ropes & Gray represented Bain Capital Life Sciences in the transaction. Serán Bioscience (“Serán”), a leading contract development and manufacturing organization (CDMO), announced a strategic growth...
Bicara Therapeutics’ $315 Million IPO
Goodwin Procter advised Bicara Therapeutics on the offering, and Ropes & Gray advised the underwriters. Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company, announced the...
Chiesi Group’s Collaboration with Gossamer Bio
Ropes & Gray advised Chiesi Group on the transaction, and Latham & Watkins advised Gossamer Bio. Chiesi Group announced it has entered into a global collaboration...
Rhythm Pharmaceuticals’ $150 Million Financing
Latham & Watkins is advising Rhythm Pharmaceuticals on the transaction, and Ropes & Gray is advising Perceptive Advisors LLC. Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (Rhythm), a commercial-stage...